Scientists believe they have improved a tool used to predict how someone will react to weight loss surgery and the probability of putting their type 2 diabetes into remission. At the moment doctors use a standard scoring system called DiaRem which combines the person’s age, body mass index (BMI), diabetes indicators and treatments to determine potential health outcomes after weight loss surgery.
Diabetes Prevention Program follow-up data add support to prior observations.
Type 2 diabetes is an independent risk factor for sudden cardiac arrest and death in patients with coronary artery disease with preserved ejection fraction.
Comparing three classes of type 2 diabetes drugs, researchers found one class, which includes Onglyza and Januvia, did not reduce death risk.
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors came out on top in a large meta-analysis of clinical trials that compared the newer classes of diabetes drugs head-to-head in terms of mortality, cardiovascular, and safety endpoints.
Trial shows that a pill version of Ozempic (semaglutide) can lower A1c by as much as 1.5% and also support weight loss.
A large number of people diagnosed with type 2 diabetes show symptoms of chronic kidney disease (CKD) before their diabetes diagnosis, researchers report. People with diabetes face an increased risk of kidney disease, but this new study reveals kidney damage could occur much earlier than expected.
Adults with type 2 diabetes who lost at least 30% of their maximum body weight had increased risks for fragility fractures and any fracture compared with those who lost less weight, according to findings published in Diabetes Care.
Study participants achieved remission to non-diabetic state
Med-IQ offers this professional webinar: Expert Insights on Insulin and GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes Mellitus (Med-IQ)